TADEKINIG ALFA- Emerging Insight and Market Forecast - 2030
|出版商||DelveInsight Business Research LLP||商品編碼||974755|
|出版日期||按訂單生產||內容資訊||英文 60 Pages
|TADEKINIG ALFA-新洞察與市場預測:2030年 TADEKINIG ALFA- Emerging Insight and Market Forecast - 2030|
|出版日期: 按訂單生產||內容資訊: 英文 60 Pages||
在人類1/1b期臨床試驗和2期臨床試驗中，已證明Tadekinig alfa具有優異的安全性和耐受性。Tadekinig alfa的早期療效跡像已在2期試驗中顯示，該藥在患有難治性成人發作Still病的患者以及NLRC4-MAS，XIAP和全身發作少年特發性關節炎的單例使用案例中顯示。
我們將通過對Tadekinig alfa從2017年到2030年銷售數據的深入分析來確定市場上Tadekinig alfa的整體情況，為客戶提供有關其治療產品組合的決策過程的支持。
本報告全面涵蓋7個主要市場上成人史迪爾氏病臨床實驗藥。提供有關2020-2030年調查期間美國，歐洲5個國家（德國，法國，意大利，西班牙，英國）和日本7個主要市場的TADEKINIG 與產品詳細內容一起提供ALFA的詳細概要。產品詳細內容中包含作用機制，劑量管理，合成途徑，法規的里程碑的研究開發活動，以及其他開發活動。再加上市場預測、 SWOT分析，市場上競爭趨勢，及其他新治療方法等未來市場趨勢。
"TADEKINIG ALFA- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets. A detailed picture of the TADEKINIG ALFA in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Tadekinig alfa is a recombinant interleukin-18 binding protein (r-hIL-18BP), that binds with high affinity to IL-18, a major inflammatory mediator. It is administered subcutaneously. In healthy people, IL-18 and IL-18BP are present constitutively in blood with a large excess of IL-18BP keeping levels of free IL-18 undetectable. However, in patients with inflammatory diseases, the IL-18/IL-18BP balance is disrupted, resulting in high levels of free and active IL-18, which leads to pathological inflammation. While the time-limited inflammatory response is a natural defense mechanism intended to clear pathogens and limit harm to the body, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases. Administration of Tadekinig alfa restores the IL-18/IL-18BP balance, by removing free IL-18 and thereby reducing inflammation.
Excellent safety and tolerability of Tadekinig alfa have been demonstrated in human subjects in Phase 1/1b clinical trials and a Phase 2 trial. Early signs of efficacy of Tadekinig alfa have been shown in a Phase 2 trial in patients suffering from refractory Adult onset Still's disease, as well in single compassionate use cases in NLRC4-MAS, XIAP, and Systemic onset Juvenile Idiopathic Arthritis.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of TADEKINIG ALFA in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of TADEKINIG ALFA covering trial interventions, trial conditions, trial status, start and completion dates.